Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
ALHC Alignment Healthcare Inc
PRGS Progress Software Corp
PMD Psychemedics Corp
RPHM Reneo Pharmaceuticals Inc
DFSU Dimensional US Sustainability Core 1 ETF
UNH UnitedHealth Group Inc
GURE Gulf Resources Inc
TDCX TDCX Inc
AMPX Amprius Technologies Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Closing Price
$821.67
Day's Change
10.17 (1.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
822.52
Day's Low
810.95
Volume
(Above Average)
Volume:
866,170

10-day average volume:
765,078
866,170

REGN's position in the Biotechnology industry

Industry PeersREGNAMGNGILDINCYUTHR

Summary

Company ProfileRegeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Go to AMGN summary
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human...
Go to GILD summary
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development...
Go to INCY summary
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso...
Go to UTHR summary
52-Week Change

VS. INDUSTRY
17.65%
-0.03%
39.56%
-9.00%
24.83%
Market Cap

VS. INDUSTRY
$89.8B
$129.1B
$103.6B
$16.1B
$10.4B
Beta

VS. INDUSTRY
0.2
0.6
0.4
0.7
0.6
Dividend Yield

VS. INDUSTRY
--
3.52%
3.62%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
21.49x
19.95x
22.81x
47.49x
14.90x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$12.2B
$26.3B
$27.3B
$3.4B
$1.9B
Profit Margin

VS. INDUSTRY
35.64%
24.89%
16.74%
10.04%
37.56%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
23.79%
1.96%
-13.86%
--
6.61%
Revenue Growth (TTM)

VS. INDUSTRY
-24.26%
1.32%
-0.09%
13.67%
14.88%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.